Nucleophosmin gene mutations in acute myeloid leukemia

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 11, 2006, Pages 1687-1692

  Chen, Weina ^a   Rassidakis, Georgios Z ^a   Medeiros, L Jeffrey ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; LEUCINE; MUTANT PROTEIN; NUCLEOPHOSMIN; PROTEIN MDM2; PROTEIN P14ARF; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CENTROSOME; CLINICAL FEATURE; CYTOGENETICS; EXON; FLT3 GENE; FRAMESHIFT MUTATION; GENE; GENE DISRUPTION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KARYOTYPE; LEUKEMOGENESIS; LEUKOCYTE COUNT; MONOCYTE; NPM1 GENE; NUCLEAR LOCALIZATION SIGNAL; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN MOTIF; REVIEW;

CYTOGENETIC ANALYSIS; GENETIC TECHNIQUES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHATIC DISEASES; MOLECULAR BIOLOGY; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PROGNOSIS; TRANSLOCATION, GENETIC;

EID: 33750601863     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Brunning RD, Matutes E, Harris NL, et al. Acute myeloid leukaemia: introduction. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology & Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001:77-80. World Health Organization Classification of Tumours.
2. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-4336.
4. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326-4335.
5. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCC study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59-66.
6. Shiah HS, Kuo YY, Tang JL, et al. Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. Leukemia. 2002;16:196-202.
7. Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol. 2002;20:3254-3261.
8. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002;100:2717-2723.
9. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352:254-266.
10. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005; 106:1419-1422.
11. Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal kayotype. Blood. 2005;106:3733-3739.
12. Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740-3746.
13. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106:2854-2861.
14. Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin NPM1 in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747-3754.
15. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106:3618-3620.
16. Chan WY, Liu QR, Borjigin J, et al. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth. Biochemistry. 1989;28:1033-1039.
17. Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell. 1989;56:379-390.
18. Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem. 2000;275:24451-24457.
19. Spector DL, Ochs RL, Busch H. Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23. Chromosoma. 1984;90:139-148.
20. Yung BY, Busch H, Chan PK. Translocation of nucleolar phosphoprotein B23 (37 kDa/pl 5.1) induced by selective inhibitors of ribosome synthesis. Biochim Biophys Acta. 1985;826:167-173.
21. Szebeni A, Herrera JE, Olson MO. Interaction of nucleolar protein B23 with peptides related to nuclear localization signals. Biochemistry, 1995;34:8037-8042.
22. Szebeni A, Olson MO. Nucleolar protein B23 has molecular chaperone activities. Protein Sci. 1999;8:905-912.
23. Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene. 2002;21:6170-6174.
24. Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol. 2004;24:985-996.
25. Korgaonkar C, Hagen J, Tompkins V, et al. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function. Mol Cell Biol. 2005;25:1258-1271.
26. Gao H, Jin S, Song Y, et al. B23 regulates GADD45a nuclear translocation and contributes to GADD45a-induced cell cycle G2-M arrest. J Biol Chem. 2005; 280:10988-10996.
27. Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol. 2002;4:529-533.
28. Redner RL, Rush EA, Faas S, Rudert WA, Corey SJ. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996;87:882-886.
29. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263:1281-1284.
30. Yoneda-Kato N, Look AT, Kirstein MN, et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene. 1996;12:265-275.
31. Nakagawa M, Kameoka Y, Suzuki R. Nucleophosmin in acute myelogenous leukemia. N Engl J Med. 2005;352:1819-1820.
32. Wang W, Budhu A, Forgues M, Wang XW. Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol. 2005;7:823-830.
33. Quentmeier H, Martelli MP, Dirks WC, et al. Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin. Leukemia. 2005;19:1760-1767.
34. Alcalay M, Tiacci E, Bergomas R, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 2005;106:899-902.
35. Engelhardt M, Lubbert M, Guo Y. CD34(+) or CD34(-): which is the more primitive? Leukemia. 2002;16:1603-1608.
36. Noguera NI, Ammatuna E, Zangrilli D, et al. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia. 2005;19:1479-1482.
37. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437:147-153.
38. den Besten W, Kuo ML, Williams RT, Sherr CJ. Myeloid leukemia-associated nucleophosmin mutants perturb p53-dependent and independent activities of the Arf tumor suppressor protein. Cell Cycle. 2005;4:1593-1598.
39. Brady SN, Yu Y, Maggi LB Jr, Weber JD. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway. Mol Cell Biol. 2004;24:9327-9338.
40. Reilly JT. FLT3 and its role in the pathogenesis of acute myeloid leukaemia. Leuk Lymphoma. 2003;44:1-7.
41. Kelly LM, Kutok JL, Williams IR, et al. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Sci U S A. 2002;99:8283-8288.
42. Gilliland DC, Tallman MS. Focus on acute leukemias. Cancer Cell. 2002; 1:417-420.